

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Mega Genomics Limited**

**美因基因有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 6667)**

### **VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE**

This announcement is made by Mega Genomics Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) of the Company and potential investors about the latest developments of the Group.

The board of directors of the Company (the “**Board**”) announces that it intends to exercise its power under the general mandate to repurchase shares of the Company (the “**Shares**”) (the “**Repurchase Mandate**”) granted to the Board by the resolution passed at the annual general meeting (the “**AGM**”) of the Company held on 9 June 2023. Pursuant to the Repurchase Mandate granted on 9 June 2023, the Company is authorized to repurchase not exceeding 23,923,380 Shares, being 10% of the total number of issued Shares as at the date of passing of the relevant resolution at the AGM. Such mandate will expire upon whichever is the earliest of: (a) the conclusion of the next annual general meeting of the Company; or (b) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held; or (c) the passing of an ordinary resolution by the Shareholders at the general meeting revoking or varying the Repurchase Mandate.

The Company will conduct the proposed share repurchase in compliance with the articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Act of the Cayman Islands and all applicable laws and regulations to which the Company is subject to.

**As at the date of this announcement, the Company has not repurchased any Shares under the Repurchase Mandate. Shareholders and potential investors should note that repurchase may be done subject to market conditions. There is no assurance of the timing, quantity or price of any repurchase or whether or not the Company will make any repurchase. Shareholders and potential investors should therefore exercise caution when dealing in the Shares.**

By Order of the Board  
**Mega Genomics Limited**  
**LIN Lin**

*Executive Director and Chairperson*

Hong Kong, 21 July 2023

*As at the date of this announcement, the executive directors of the Company are Dr. Yu Rong, Ms. Lin Lin, Mr. Huang Yufeng and Ms. Jiang Jing; the non-executive director of the Company is Ms. Guo Meiling; and the independent non-executive directors of the Company are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.*

\* *For identification purpose only*